Kazia Therapeutics (NASDAQ: KZIA) reported preliminary clinical responses from its ongoing Phase 1b study of paxalisib in patients with late-stage ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE